Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Neuromuscular Disorders : NMD
|
July 6, 2019
European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials
Marion Haberkamp, Jane Moseley, Dimitrios Athanasiou, et al.
Nature Reviews. Drug Discovery
|
April 2, 2015
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease
Manuel Haas, Valentina Mantua, Marion Haberkamp, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
December 15, 2023
The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers
Florence Butlen-Ducuing, Marion Haberkamp, Georgios Aislaitner, et al.
The Lancet Regional Health. Europe
|
March 19, 2026
Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
Lorenzo Guizzaro, Ewa Bałkowiec-Iskra, Marion Haberkamp, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
January 15, 2014
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval
Anabel Cortes-Blanco, Concha Prieto-Yerro, Raul Martinez-Lazaro, et al.
ACS Pharmacology & Translational Science
|
August 14, 2025
Applying the EU Regulatory Framework to Determine the Benefit-Risk Profile of Psychedelics
Kate Browne, Ewa Bałkowiec-Iskra, Andre Elferink, et al.
Neuroscience Applied
|
July 14, 2025
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
Drummond E-Wen McCulloch, Matthias E Liechti, Kim Pc Kuypers, et al.
Neuropharmacology
|
May 15, 2020
Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery
Harald Hampel, Andrea Vergallo, Filippo Caraci, et al.
Dialogues in Clinical Neuroscience
|
October 23, 2019
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
Harald Hampel, Andrea Vergallo, Mohammad Afshar, et al.
Pharmacological Research
|
February 20, 2018
Precision pharmacology for Alzheimer's disease
Harald Hampel, Andrea Vergallo, Lisi Flores Aguilar, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Neuromuscular Disorders : NMD
|
July 6, 2019
European regulators' views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials
Marion Haberkamp, Jane Moseley, Dimitrios Athanasiou, et al.
Nature Reviews. Drug Discovery
|
April 2, 2015
The European Medicines Agency's strategies to meet the challenges of Alzheimer disease
Manuel Haas, Valentina Mantua, Marion Haberkamp, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
December 15, 2023
The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers
Florence Butlen-Ducuing, Marion Haberkamp, Georgios Aislaitner, et al.
The Lancet Regional Health. Europe
|
March 19, 2026
Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab
Lorenzo Guizzaro, Ewa Bałkowiec-Iskra, Marion Haberkamp, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
January 15, 2014
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval
Anabel Cortes-Blanco, Concha Prieto-Yerro, Raul Martinez-Lazaro, et al.
ACS Pharmacology & Translational Science
|
August 14, 2025
Applying the EU Regulatory Framework to Determine the Benefit-Risk Profile of Psychedelics
Kate Browne, Ewa Bałkowiec-Iskra, Andre Elferink, et al.
Neuroscience Applied
|
July 14, 2025
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
Drummond E-Wen McCulloch, Matthias E Liechti, Kim Pc Kuypers, et al.
Neuropharmacology
|
May 15, 2020
Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery
Harald Hampel, Andrea Vergallo, Filippo Caraci, et al.
Dialogues in Clinical Neuroscience
|
October 23, 2019
Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
Harald Hampel, Andrea Vergallo, Mohammad Afshar, et al.
Pharmacological Research
|
February 20, 2018
Precision pharmacology for Alzheimer's disease
Harald Hampel, Andrea Vergallo, Lisi Flores Aguilar, et al.
Page
of 2